AIM:To compare clinical effects of intravitreal injection of anti-vascular endothelial growth factor(VEGF)medicine for proliferative diabetic retinopathy(PDR).

METHODS: Eighty-four patients with PDR(84 eyes)in our hospital in January 2010 to January 2015 were selected, and were randomly divided into three groups(A, B, C, 28 eyes of 28 cases ). The patients in group A underwent vitrectomy, those in group B received intravitreal injection of ranibizumab before vitrectomy; and those in group C got intravitreal injection of conbercept before vitrectomy. Operative time, complications, and postoperative best-corrected visual acuity at 6mo of the three groups were compared.

RESULTS: After treatment, the incidence of intraoperative and postoperative complications and the operation time of group B and group C were lower than those of group A. Compared best corrected visual acuity at preoperative and postoperative 6mo, and among three groups, there were no statistically significance difference(P<0.05). There were no statistical differences compared visual acuity improvement among three groups(P>0.05).

CONCLUSION: Intravitreal injection of ranibizumab and conbercept before vitrectomy can decrease the operation time and intraoperative bleeding, reduce the incidence of intraoperative and postoperative complications and improve BCVA of patients in the treatment of PDR.